Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.
Fiche publication
Date publication
mars 2019
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr MARILIER Sophie, Dr QUIPOURT Valérie, Dr VINCENT Julie, Pr SCHMITT Antonin
Tous les auteurs :
Macaire P, Morawska K, Vincent J, Quipourt V, Marilier S, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A
Lien Pubmed
Résumé
Most clinical trials exclude elderly people, leading to a limited understanding of the benefit-to-risk ratio in this population. Despite existing data regarding the oncological management of elderly receiving fluorouracil (5-FU)-based regimen, our objective was to investigate 5-FU exposure/toxicity relationship in patients ≥75 years and compare the effectiveness of 5-FU therapeutic drug monitoring between elderly and younger patients.
Mots clés
5-Fluorouracil, Elderly, Gastrointestinal cancer, Therapeutic drug monitoring
Référence
Eur. J. Cancer. 2019 Mar 5;111:116-125